Literature DB >> 8662595

Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists.

K R Hudson1, A B Vernallis, J K Heath.   

Abstract

Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity. The region of hLIF most important for binding to the hLIF-R is composed of residues from the amino terminus of the D-helix, carboxyl terminus of the B-helix, and C-D loop. This site forms a distinct surface at the end of the four-helix bundle in the tertiary structure of the closely related murine LIF. The two residues of hLIF that contribute the majority of free energy for hLIF-R binding, Phe-156 and Lys-159 are surrounded by other residues which have only a moderate impact. This arrangement of a few key residues surrounded by less important ones is analogous to the functional binding epitope of human growth hormone for its receptor. A second region of hLIF that includes residues from the carboxyl terminus of the D-helix and A-B loop also had a weak influence on hLIF-R binding. Residues in hLIF from both the A- and C-helices are involved in binding the gp130 co-receptor. Abolition of the gp130 binding site in hLIF created antagonists of LIF action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662595     DOI: 10.1074/jbc.271.20.11971

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Late retinal progenitor cells show intrinsic limitations in the production of cell types and the kinetics of opsin synthesis.

Authors:  M J Belliveau; T L Young; C L Cepko
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

Review 2.  Receptor recognition by gp130 cytokines.

Authors:  J Bravo; J K Heath
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution.

Authors:  J G Zhang; C M Owczarek; L D Ward; G J Howlett; L J Fabri; B A Roberts; N A Nicola
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

4.  Birth control vaccine targeting leukemia inhibitory factor.

Authors:  Angela R Lemons; Rajesh K Naz
Journal:  Mol Reprod Dev       Date:  2011-12-02       Impact factor: 2.609

5.  Crystal structure of a cytokine-binding region of gp130.

Authors:  J Bravo; D Staunton; J K Heath; E Y Jones
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

6.  Intracellular and extracellular leukemia inhibitory factor proteins have different cellular activities that are mediated by distinct protein motifs.

Authors:  B P Haines; R B Voyle; P D Rathjen
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

7.  The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.

Authors:  Juan M Adrian-Segarra; Natalie Schindler; Praveen Gajawada; Holger Lörchner; Thomas Braun; Jochen Pöling
Journal:  J Biol Chem       Date:  2018-03-06       Impact factor: 5.157

8.  Functional characterization of W147A: a high-affinity interleukin-11 antagonist.

Authors:  Nicholas Underhill-Day; Lisa A McGovern; Natalia Karpovich; Helen J Mardon; Victoria A Barton; John K Heath
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

9.  Characterization of a potent human interleukin-11 agonist.

Authors:  Dimitri Harmegnies; Xiao-Ming Wang; Paul Vandenbussche; Arnaud Leon; Patricia Vusio; Joachim Grötzinger; Yannick Jacques; Erik Goormaghtigh; Bart Devreese; Jean Content
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

10.  Molecular dissection of human interleukin-31-mediated signal transduction through site-directed mutagenesis.

Authors:  Sabine Le Saux; François Rousseau; Fabien Barbier; Elisa Ravon; Linda Grimaud; Yannic Danger; Josy Froger; Sylvie Chevalier; Hugues Gascan
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.